Compare Bristol-Myers Squibb Co (BMY) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs JPMorgan Chase & Co — how do they compare? Bristol-Myers Squibb Co trades at $63.88 (market cap $130.12B), while JPMorgan Chase & Co trades at $367.75 (market cap $970.72B). The key difference: JPMorgan Chase & Co is far larger — about 7.5× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | JPM | |
|---|---|---|
Market Cap | $130.12B | $970.72B |
Sector | Health | Financials |
52-Week High | $65.89 | $365.18 |
52-Week Low | $42.60 | $282.84 |
Enterprise Value | $164.11B | — |
Dividend Yield | 3.96% | 1.64% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
JPMorgan Chase (JPM) trades at $362.04, up 0.63% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent quarterly earnings have largely beaten expectations, with Q2 2026 EPS of $7.59 surpassing the $5.59 estimate. The company maintains strong profitability with a net income margin of 33.38% and ROE of 18.43%, though cash flow from operations was negative in 2025.
The outlook for JPM is positive, supported by solid earnings performance and a 'Moderate Buy' analyst rating. Key opportunities include revenue growth and high ROE, while risks involve geopolitical tensions, cybersecurity threats highlighted in recent news, and volatile cash flow trends. The stock presents a stable investment in the financial sector with upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
